Metoprolol Succinate Extended-Release Tablets — Class II drug recall D-0357-2026
Ongoing recall by Teva Pharmaceuticals USA, Inc, reported 2026-03-11, distributed nationwide. Failed Dissolution Specifications
| Recall number | D-0357-2026 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teva Pharmaceuticals USA, Inc, Parsippany, NJ, United States |
| Recall initiated | 2026-01-29 |
| Classified | 2026-02-27 |
| Reported by FDA | 2026-03-11 |
| Distributed | Nationwide (US) |
| Quantity | 19,056 bottles |
| Reason classes | specification failure |
| NDC | 45963-0676, 45963-0676-11, 45963-0676-96, 45963-0677, 45963-0677-11, 45963-0677-96, 45963-0678, 45963-0678-11, 45963-0709, 45963-0709-11, 45963-0709-96 |
| Expiration dates | 2027-02 |
Product
Metoprolol Succinate Extended-Release Tablets, 200 mg, 100 tablets bottles, Rx Only, Teva Pharmaceuticals, Parsippany, NJ 07054, NDC: 45963-678-11
Reason for recall
Failed Dissolution Specifications
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0357-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.